Andrew Haddad

Andrew Haddad

Auto-generated profile, based on publicly available information

Andrew Haddad

Department of Pharmaceutical Sciences University of Pittsburgh School of Pharmacy Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
ATAmy J. Turner
Amy J. Turner
CHCyrine E. Haidar
Cyrine E. Haidar
WYWenjian Yang
Wenjian Yang
EBErin C. Boone
Erin C. Boone
SOSteven M. Offer
Steven M. Offer
AGAndrea Gaedigk
Andrea Gaedigk
The DPYD gene encodes dihydropyrimidine dehydrogenase, the rate‐limiting enzyme for the metabolism of fluoropyrimidines 5‐fluorouracil and capecitabine. Genetic variants in DPYD have been associated with altered enzyme activity, therefore accurate detection and interpretation is critical to predict metabolizer status for individualized fluoropyrimidine therapy. The most commonly observed deleterious variation is the causal variant linked to the previously described HapB3 haplotype, c.1129‐5923C>G (rs75017182) in intron 10, which introduces a cryptic splice site. A benign synonymous variant in exon 11, c.1236G>A (rs56038477) is also linked to HapB3 and is commonly used for testing. Previously, these single‐nucleotide polymorphisms (SNPs) have been reported to be in perfect linkage disequilibrium (LD); therefore, c.1236G>A is often utilized as a proxy for the function‐altering intronic variant. Clinical genotyping of DPYD identified a patient who had c.1236G>A, but not c.1129‐5923C>G, suggesting that these two SNPs may not be in perfect LD, as previously assumed. Additional individuals with c.1236G>A, but not c.1129‐5923C>G, were identified in the Children's Mercy Data Warehouse and the All of Us Research Program version 7 cohort substantiating incomplete SNP linkage. Consequently, testing only c.1236G>A can generate false‐positive results in some cases and lead to suboptimal dosing that may negatively impact patient therapy and prospect of survival. Our data show that DPYD genotyping should include the functional variant c.1129‐5923C>G, and not the c.1236G>A proxy, to accurately predict DPD activity.

8 December 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
JWJulia Wynn
Julia Wynn
AHAndrew Haddad
Andrew Haddad
JHJennifer Hoskovec
Jennifer Hoskovec
HBHaywood L. Brown
Haywood L. Brown

11 November 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
AHAndrew Haddad
Andrew Haddad
ARAparna Radhakrishnan
Aparna Radhakrishnan
SMSean McGee
Sean McGee
JSJoshua D. Smith
Joshua D. Smith
JKJason H. Karnes
Jason H. Karnes
SZStephan Zuchner
Stephan Zuchner
Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in pharmacogenomics studies impedes clinical translation and the application of precision medicine across populations. We evaluated the frequencies of variants in 16 pharmacogenes ( ABCG2 , CACNA1S , CYP2D6 , CYP2C Cluster , CYP2C19 , CYP2C9 , CYP3A5 , CYP4F2 , DPYD , G6PD , NUDT15 , RYR1 , SLCO1B1 , TPMT , UGT1A1 , and VKORC1 ) and predicted phenotypes and medication exposures using whole-genome sequencing and electronic health record data from nearly 100,000 All of Us Research Program participants. We report that 100% of participants carried at least one pharmacogenomic variant and nearly all (99.5%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with 24.4% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we report thousands of previously unrecognized pharmacogene variants and hundreds of alleles and predicted phenotypes that deviate from known frequencies across populations or were previously unreported, especially in the Americas and African ancestry groups.

31 July 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
ATAmy J. Turner
Amy J. Turner
EBErin C. Boone
Erin C. Boone
CHCyrine E. Haidar
Cyrine E. Haidar
WYWenjian Yang
Wenjian Yang
ADAshley D. Derezinski
Ashley D. Derezinski
AGAndrea Gaedigk
Andrea Gaedigk
CYP2C19 plays an important role in the metabolism of many medications, including the antiplatelet agent clopidogrel, the antifungal agent voriconazole, selective serotonin reuptake inhibitors, select tricyclic antidepressants, and proton pump inhibitors. The Clinical Pharmacogenetics Implementation Consortium has published several guidelines emphasizing the importance of CYP2C19 genotype‐guided therapy to optimize patient outcomes. Formerly, the no function CYP2C19*2 allele was defined by three variants, c.332‐23A>G (splice defect), c.681G>A (splice defect), and c.991A>G (p.I331V). The discovery of two new haplotypes, one containing only a single variant, c.681G>A, and another with only c.681G>A and c.991A>G, challenged the assumption that c.681G>A always occurred together with c.332‐23A>G. PharmVar designated these new haplotypes as CYP2C19*2.018 and *2.019 , respectively, prompting the revision of the CYP2C19*2 core allele to be defined solely by the single variant, c.681G>A. Although the variants interrogated to identify CYP2C19*2 and *35 remain the same, subjects who are heterozygous for c.332‐23A>G (present on most CYP2C19*2 and all *35 alleles) and c.681G>A (present on all CYP2C19*2 alleles) may, in rare cases, have a CYP2C19*2/*35 poor metabolizer diplotype (variants in trans ) and not a CYP2C19*1/*2 intermediate metabolizer diplotype (variants in cis ). CYP2C19*2 alleles with c.681G>A, but not c.332‐23A>G, were found in subjects across diverse populations and are estimated to have a frequency around 0.03%. These findings, along with the revision of the CYP2C19*2 core allele definition, have implications for variant testing, test interpretation and reporting.